Table 1. Demographic characteristics of each cohort.
Patient number, gender, age and diagnosis for each cohort. Data are shown as the n (%) or median (IRQ). LEAP (lupus extended autoimmune phenotype) cohort: see Reynolds et al. [16]. Rodero et al. cohort: see reference 13. ASSESS (assessment of systemic complications (signs) and evolution in Sjögren’s syndrome) cohort: see Bost et al. (In review). Menon et al. cohort: paper in preparation. C10-08 cohort: see Sultanik et al. [17]. Upasani et al. cohort: see reference 18. MCTD: mixed CTD. UCDT: undifferentiated CTD. pSS: primary Sjögren’s syndrome. SLE: systemic lupus erythematosus. CTD: connective tissue disease. JSLE : juvenile SLE. CNS: central nervous system. cHCV: chronic hepatitis C virus infection. DF: dengue fever. DHF: dengue haemorrhagic fever. DSS: dengue shock syndrome.
| Cohorts used in this study (patients included only) | ||||
|---|---|---|---|---|
| Cohort | Patient number | Gender, female | Age | Diagnosis |
| LEAP | 84 | 79 (94%) | 49 (36-57) | MCTD: 6 (7%) UCTD: 27 (32%) pSS: 12 (14%) SLE: 39 (46%) |
| Rodero et al. (2017) | 93 | 76 (82%) | 42 (26-54) | CTD: 19 (20%) JSLE: 6 (6%) SLE: 50 (54%) Viral CNS infection: 18 (19%) |
| ASSESS | 380 | 353 (93%) | 59 (51-67) | pSS: 380 (100%) |
| Menon et al. (in preparation) | 111 | 100 (90%) | 53 (40-63) | SLE: 111 (100%) |
| C10-08 | 88 | 41 (47%) | 58 (50-65) | cHCV: 88 (100%) |
| Upasani et al. (2020) | 56 | 27 (48%) | 10 (6-12) | DF: 46 (82%) DHF: 7 (13%) DSS : 3 (5%) |
| Clinical diagnosis cohorts | ||||
| Cohort | Patient number | Gender, female | Age | |
| CTD | 52 | 48 (92%) | 48 (33-53) | |
| pSS | 392 | 365 (93%) | 58 (51-67) | |
| SLE | 206 | 189 (92%) | 50 (38-60) | |
| cHCV | 88 | 41 (47%) | 58 (50-65) | |
| Dengue | 56 | 27 (48%) | 10 (6-12) | |
| Viral CNS infection | 18 | 6 (33%) | 2(<1-31) | |